Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of MGL-3196 Tablets vs Capsules
NCT03413124Phase 1Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of resmetirom in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoint: Area under the curve from the time of dosing extrapolated to infinity at 48 hours. Started Feb 2018; status: completed.
02
Drugs
resmetirom
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03413124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03413124.